Phase I Trial of Everolimus and Capecitabine in Metastatic HER2- Breast Cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Clinical breast cancer"
DOI: 10.1016/j.clbc.2017.03.003
Abstract: BACKGROUND The mammalian target of rapamycin (mTOR) pathway is a driver of breast tumorigenesis. The mTOR inhibitor everolimus reverses antihormonal therapy resistance and is an approved therapy for metastatic breast cancer. A synergistic effect with… read more here.
Keywords: everolimus capecitabine; capecitabine; breast; breast cancer ... See more keywords